Agios Pharmaceuticals, Inc.
AGIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $36 | $27 | $14 | $0 |
| % Growth | 36.1% | 88.4% | – | – |
| Cost of Goods Sold | $4 | $10 | $2 | $19 |
| Gross Profit | $32 | $17 | $13 | -$19 |
| % Margin | 88.6% | 64.6% | 88% | – |
| R&D Expenses | $301 | $289 | $280 | $257 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $157 | $120 | $122 | $121 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$19 |
| Operating Expenses | $458 | $409 | $402 | $360 |
| Operating Income | -$426 | -$391 | -$389 | -$378 |
| % Margin | -1,166.5% | -1,459.5% | -2,732.1% | – |
| Other Income/Exp. Net | $1,144 | $39 | $157 | $22 |
| Pre-Tax Income | $718 | -$352 | -$232 | -$357 |
| Tax Expense | $44 | $0 | $0 | $0 |
| Net Income | $674 | -$352 | -$232 | $1,605 |
| % Margin | 1,845.9% | -1,312.6% | -1,627.8% | – |
| EPS | 11.86 | -6.33 | -4.23 | -6.36 |
| % Growth | 287.4% | -49.6% | 33.5% | – |
| EPS Diluted | 11.64 | -6.33 | -4.23 | -6.36 |
| Weighted Avg Shares Out | 57 | 56 | 55 | 60 |
| Weighted Avg Shares Out Dil | 58 | 56 | 55 | 60 |
| Supplemental Information | – | – | – | – |
| Interest Income | $48 | $33 | $13 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $6 | $7 | $9 | $19 |
| EBITDA | -$420 | -$385 | -$380 | -$338 |
| % Margin | -1,151% | -1,434.8% | -2,671.9% | – |